Impacts of hyper-homocysteinemia and white matter hyper-intensity in Alzheimer's disease patients with normal creatinine: An MRI-based study with longitudinal follow-up

Current Alzheimer Research

Volumn 7, Issue 6, 2010, Pages 527-533

  Huang, C W ^a   Chang, W N ^a   Lui, C C ^a   Chen, C F ^a   Lu, C H ^a   Wang, Y L ^a   Chen, C ^a   Juang, Y Y ^a   Lin, Y T ^a   Tu, M C ^a   Chang, C C ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Alzheimer's disease; Cognitive decline; FLAIR; Homocysteine; White matter

Indexed keywords

CREATININE; HOMOCYSTEINE;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN DISEASE; COGNITION; DEMENTIA; HEALTH SURVEY; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK FACTOR; WHITE MATTER; WHITE MATTER HYPERINTENSITY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; BLOOD GLUCOSE; BRAIN; CHOLESTEROL; CROSS-SECTIONAL STUDIES; FASTING; FEMALE; HOMOCYSTEINE; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MENTAL STATUS SCHEDULE; NERVE FIBERS, MYELINATED; NEUROPSYCHOLOGICAL TESTS;

EID: 78549235054     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720510792231702     Document Type: Article

References (50)

1. Varela-Moreiras G, Murphy MM, Scott JM. Cobalamin, folic acid, and homocysteine. Nutr Rev 67 (Suppl 1): S69-72 (2009).
2. McCaddon A, Davies G, Hudson P, Tandy S, Cattell H. Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 13: 235-239 (1998).
3. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346: 476-483 (2002).
4. Sachdev P. Homocysteine, cerebrovascular disease and brain atrophy. J Neurol Sci 226: 25-29 (2004).
5. Prins ND, Den Heijer T, Hofman A, Koudstaal PJ, Jolles J, Clarke R, et al. Homocysteine and cognitive function in the elderly: the Rotterdam Scan Study. Neurology 59: 1375-1380 (2002).
6. McCaddon A, Hudson P, Davies G, Hughes A, Williams JH, Wilkinson C. Homocysteine and cognitive decline in healthy elderly. Dement Geriatr Cogn Disord 12: 309-313 (2001).
7. Duan JH, Wang HQ, Xu J, Lin X, Chen SQ, Kang Z, et al. White matter damage of patients with Alzheimer's disease correlated with the decreased cognitive function. Surg Radiol Anat 28: 150-156 (2006).
8. Rosendorff C, Beeri MS, Silverman JM. Cardiovascular risk factors for Alzheimer's disease. Am J Geriatr Cardiol 16: 143-149 (2007).
9. Fazekas F, Kleinert R, Offenbacher H, Schmidt R, Kleinert G, Payer F, et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology 43: 1683-1689 (1993).
10. Mantyla R, Aronen HJ, Salonen O, Pohjasvaara T, Korpelainen M, Peltonen T, et al. Magnetic resonance imaging white matter hyperintensities and mechanism of ischemic stroke. Stroke 30: 2053-2058 (1999).
11. Bondareff W, Raval J, Colletti PM, Hauser DL. Quantitative magnetic resonance imaging and the severity of dementia in Alzheimer's disease. Am J Psychiatry 145: 853-856 (1988).
12. Leys D, Soetaert G, Petit H, Fauquette A, Pruvo JP, Steinling M. Periventricular and white matter magnetic resonance imaging hyperintensities do not differ between Alzheimer's disease and normal aging. Arch Neurol 47: 524-527 (1990).
13. Seshadri S, Wolf PA, Beiser AS, Selhub J, Au R, Jacques PF, et al. Association of plasma total homocysteine levels with subclinical brain injury: cerebral volumes, white matter hyperintensity, and silent brain infarcts at volumetric magnetic resonance imaging in the Framingham Offspring Study. Arch Neurol 65: 642-649 (2008).
14. Dufouil C, Alperovitch A, Ducros V, Tzourio C. Homocysteine, white matter hyperintensities, and cognition in healthy elderly people. Ann Neurol 53: 214-221 (2003).
15. Hogervorst E, Ribeiro HM, Molyneux A, Budge M, Smith AD. Plasma homocysteine levels, cerebrovascular risk factors, and cerebral white matter changes (leukoaraiosis) in patients with Alzheimer disease. Arch Neurol 59: 787-793 (2002).
16. Murray AM. Cognitive impairment in the aging dialysis and chronic kidney disease populations: an occult burden. Adv Chronic Kidney Dis 15: 123-132 (2008).
17. van Guldener C, Stam F, Stehouwer CD. Hyperhomocysteinaemia in chronic kidney disease: focus on transmethylation. Clin Chem Lab Med 43: 1026-1031 (2005).
18. American psychiatric associations diagnostic and statistical manual of mental disorders, ed 4 (dsm-iv) Washington: American Psychiatric Association (1994).
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944 (1984).
20. Rockwood K, Strang D, MacKnight C, Downer R, Morris JC. Interrater reliability of the clinical dementia rating in a multicenter trial. J Am Geriatr Soc 48: 558-559 (2000).
21. Gavin JR, 3rd. New classification and diagnostic criteria for diabetes mellitus. Clin Cornerstone 1: 1-12 (1998).
22. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289: 2560-2572 (2003).
23. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 7: 486-488 (1980).
24. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198 (1975).
25. Ylikoski R, Ylikoski A, Erkinjuntti T, Sulkava R, Raininko R, Tilvis R. White matter changes in healthy elderly persons correlate with attention and speed of mental processing. Arch Neurol 50: 818-824 (1993).
26. Pantoni L, Simoni M, Pracucci G, Schmidt R, Barkhof F, Inzitari D. Visual rating scales for age-related white matter changes (leukoaraiosis): can the heterogeneity be reduced? Stroke 33: 2827-2833 (2002).
27. Fazekas F, Niederkorn K, Schmidt R, H Offenbacher, S Horner, G Bertha et al. White matter signal abnormalities in normal individuals: correlation with carotid ultrasonography, cerebral blood flow measurements, and cerebrovascular risk factors. Stroke 19: 1285-1288 (1988).
28. Scheltens P, Erkinjunti T, Leys D, Wahlund L-O, Inzitari D, del Ser T, et al. White matter changes on CT and MRI: an overview of visual rating scales. European Task Force on age-related white matter changes. Eur Neurol 39: 80-89 (1998).
29. Gorelick PB. William M. Feinberg Lecture: Cognitive vitality and the role of stroke and cardiovascular disease risk factors. Stroke 36: 875-879 (2005).
30. Tucker KL, Qiao N, Scott T, Rosenberg I, Spiro A, 3rd. High homocysteine and low B vitamins predict cognitive decline in aging men: the Veterans Affairs Normative Aging Study. Am J Clin Nutr 82: 627-635 (2005).
31. Luchsinger JA, Tang MX, Shea S, Miller J, Green R, Mayeux R. Plasma homocysteine levels and risk of Alzheimer disease. Neurology 62: 1972-1976 (2004).
32. Oulhaj A, Refsum H, Beaumont H, Williams J, King E, Jacoby R, et al. Homocysteine as a predictor of cognitive decline in Alzheimer's disease. Int J Geriatr Psychiatry 25: 82-90.
33. Connelly P. High dose vitamin B supplementation does not slow cognitive decline in mild to moderate Alzheimer's disease. Evid Based Ment Health 12: 86 (2009).
34. Stampfer MJ. Cardiovascular disease and Alzheimer's disease: common links. J Intern Med 260: 211-223 (2006).
35. Poddar R, Paul S. Homocysteine-NMDA receptor-mediated activation of extracellular signal-regulated kinase leads to neuronal cell death. J Neurochem 110: 1095-1106 (2009).
36. Perla-Kajan J, Twardowski T, Jakubowski H. Mechanisms of homocysteine toxicity in humans. Amino Acids 32: 561-572 (2007).
37. Boldyrev AA. Molecular mechanisms of homocysteine toxicity. Biochemistry (Mosc) 74: 589-598 (2009).
38. Kalmijn S, Launer LJ, Lindemans J, Bots ML, Hofman A, Breteler MM. Total homocysteine and cognitive decline in a communitybased sample of elderly subjects: the Rotterdam Study. Am J Epidemiol 150: 283-289 (1999).
39. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging 3: 211-225 (2008).
40. Esiri MM, Nagy Z, Smith MZ, Barnetson L, Smith AD. Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. Lancet 354: 919-920 (1999).
41. Nagy Z, Esiri MM, Jobst KA, Morris JH, King EM-F, McDonald B, et al. The effects of additional pathology on the cognitive deficit in Alzheimer disease. J Neuropathol Exp Neurol 56: 165-170 (1997).
42. Regan C, Katona C, Walker Z, Hooper J, Donovan J, Livingston G. Relationship of vascular risk to the progression of Alzheimer disease. Neurology 67: 1357-1362 (2006).
43. Kertesz A, Polk M, Carr T. Cognition and white matter changes on magnetic resonance imaging in dementia. Arch Neurol 47: 387-391 (1990).
44. Spilt A, Goekoop R, Westendorp RG, Blauw GJ, de Craen AJ, van Buchem MA. Not all age-related white matter hyperintensities are the same: a magnetization transfer imaging study. AJNR Am J Neuroradiol 27: 1964-1968 (2006).
45. Kelley RE. Ischemic demyelination. Neurol Res 28: 334-340 (2006).
46. Guidetti D, Casali B, Mazzei RL, Dotti MT. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Clin Exp Hypertens 28: 271-277 (2006).
47. Neuropathology Group. Medical Research Council Cognitive F, Aging S. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 357: 169-175 (2001).
48. Black S, Gao F, Bilbao J. Understanding white matter disease: imaging-pathological correlations in vascular cognitive impairment. Stroke 40: S48-52 (2009).
49. Lipton SA, Kim WK, Choi YB, Kumar S, D'Emilia DM, Rayudu PV, et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 94: 5923-5928 (1997).
50. Matsusue E, Sugihara S, Fujii S, Ohama E, Kinoshita T, Ogawa T. White matter changes in elderly people: MR-pathologic correlations. Magn Reson Med Sci 5: 99-104 (2006).